Journal of Antimicrobial Chemotherapy, Vol 41, 37-46, Copyright © 1998 by The British Society for Antimicrobial Chemotherapy
MT Labro
The important role played by macrolides in the chemotherapy of infectious
diseases is well established, but there is still much speculation about
their anti-inflammatory potential. A review of in- vitro and ex-vivo
studies reported in the literature shows that macrolides have potentially
relevant immunomodulatory effects. In-vitro data suggest that erythromycin
A derivatives have a direct effect on neutrophil function and the
production of cytokines involved in the inflammation cascade. The ex-vivo
results indicate that short-term administration of macrolides may enhance
the immune response while long- term administration results in
immunosuppression. Further research is required to improve our
understanding of the therapeutic activity of macrolides.
ORIGINAL ARTICLES
Anti-inflammatory activity of macrolides: a new therapeutic potential?
Inserm U479, Service d'Hematologie et d'Immunologie Biologiques, CHU Xavier Bichat, Paris, France.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. N. Sleiman, S. A. Kohlhoff, P. M. Roblin, S. Wallner, R. Gross, M. R. Hammerschlag, M. E. Zenilman, and M. H. Bluth Sophorolipids as Antibacterial Agents Ann. Clin. Lab. Sci., January 1, 2009; 39(1): 60 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Kremer, R. G. Zwerdling, P. H. Michelson, and B. P. O'Sullivan Intensive Care Management of the Patient With Cystic Fibrosis J Intensive Care Med, May 1, 2008; 23(3): 159 - 177. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Hoffmann, B. Lee, M. Hentzer, T. B. Rasmussen, Z. Song, H. K. Johansen, M. Givskov, and N. Hoiby Azithromycin Blocks Quorum Sensing and Alginate Polymer Formation and Increases the Sensitivity to Serum and Stationary-Growth-Phase Killing of Pseudomonas aeruginosa and Attenuates Chronic P. aeruginosa Lung Infection in Cftr / Mice Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3677 - 3687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. V. Hawkyard and R. J. Koerner The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks J. Antimicrob. Chemother., March 1, 2007; 59(3): 347 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Tahan, A. Ozcan, and N. Koc Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial Eur. Respir. J., January 1, 2007; 29(1): 91 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Lotter, K. Hocherl, M. Bucher, and F. Kees In vivo efficacy of telithromycin on cytokine and nitric oxide formation in lipopolysaccharide-induced acute systemic inflammation in mice J. Antimicrob. Chemother., September 1, 2006; 58(3): 615 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Berman, D. Hasdai, E. Raanani, G. P. Georghiou, L. Kapustin, Y. Chepurko, B. A. Vidne, and E. Hochhauser Ex-vivo effect of roxithromycin on human and rat arterial vasoactivity Interactive CardioVascular and Thoracic Surgery, June 1, 2005; 4(3): 232 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Barker, D. J. Gillie, M. S. Schechter, and B. K. Rubin Effect of Macrolides on In Vivo Ion Transport across Cystic Fibrosis Nasal Epithelium Am. J. Respir. Crit. Care Med., April 15, 2005; 171(8): 868 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S C Bell, S L Senini, and J G McCormack Macrolides in cystic fibrosis Chronic Respiratory Disease, April 1, 2005; 2(2): 85 - 98. [Abstract] [PDF]
|
|
|
|
 |
|
 S. A Voils, M. E Evans, M. T Lane, R. H Schosser, and R. P Rapp Use of Macrolides and Tetracyclines for Chronic Inflammatory Diseases Ann. Pharmacother., January 1, 2005; 39(1): 86 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Tsai, M. L. Rodriguez, K. S. Young, J. C. Deng, V. J. Thannickal, K. Tateda, M. B. Hershenson, and T. J. Standiford Azithromycin Blocks Neutrophil Recruitment in Pseudomonas Endobronchial Infection Am. J. Respir. Crit. Care Med., December 15, 2004; 170(12): 1331 - 1339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Matsuoka, M. Narita, N. Okazaki, H. Ohya, T. Yamazaki, K. Ouchi, I. Suzuki, T. Andoh, T. Kenri, Y. Sasaki, et al. Characterization and Molecular Analysis of Macrolide-Resistant Mycoplasma pneumoniae Clinical Isolates Obtained in Japan Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4624 - 4630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Tormakangas, H. Alakarppa, D. B. David, M. Leinonen, and P. Saikku Telithromycin Treatment of Chronic Chlamydia pneumoniae Infection in C57BL/6J mice Antimicrob. Agents Chemother., October 1, 2004; 48(10): 3655 - 3661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Basyigit, F. Yildiz, S. K. Ozkara, E. Yildirim, H. Boyaci, and A. Ilgazli The Effect of Clarithromycin on Inflammatory Markers in Chronic Obstructive Pulmonary Disease: Preliminary Data Ann. Pharmacother., September 1, 2004; 38(9): 1400 - 1405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Schultz Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis J. Antimicrob. Chemother., July 1, 2004; 54(1): 21 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Labro, H. Abdelghaffar, and C. Babin-Chevaye Interaction of the New Ketolide ABT-773 (Cethromycin) with Human Polymorphonuclear Neutrophils and the Phagocytic Cell Line PLB-985 In Vitro Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1096 - 1104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Gibson, J. L. Burns, and B. W. Ramsey Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis Am. J. Respir. Crit. Care Med., October 15, 2003; 168(8): 918 - 951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Saiman, B. C. Marshall, N. Mayer-Hamblett, J. L. Burns, A. L. Quittner, D. A. Cibene, S. Coquillette, A. Y. Fieberg, F. J. Accurso, and P. W. Campbell III Azithromycin in Patients With Cystic Fibrosis Chronically Infected With Pseudomonas aeruginosa: A Randomized Controlled Trial JAMA, October 1, 2003; 290(13): 1749 - 1756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. F. Berg, B. Maraha, G.-J. Scheffer, M. F. Peeters, and J. A. J. W. Kluytmans Effect of Clarithromycin on Inflammatory Markers in Patients with Atherosclerosis Clin. Vaccine Immunol., July 1, 2003; 10(4): 525 - 528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Hardy, A. M. Rios, S. Chavez-Bueno, H. S. Jafri, J. Hatfield, B. B. Rogers, G. H. McCracken, and O. Ramilo Antimicrobial and Immunologic Activities of Clarithromycin in a Murine Model of Mycoplasma pneumoniae-Induced Pneumonia Antimicrob. Agents Chemother., May 1, 2003; 47(5): 1614 - 1620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Higgins Chlamydia pneumoniae and Coronary Artery Disease: The Antibiotic Trials Mayo Clin. Proc., March 1, 2003; 78(3): 321 - 332. [Abstract] [PDF]
|
|
|
|
 |
|
 K. W. Garey, A. Alwani, L. H. Danziger, and I. Rubinstein Tissue Reparative Effects of Macrolide Antibiotics in Chronic Inflammatory Sinopulmonary Diseases Chest, January 1, 2003; 123(1): 261 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yoshii, S. Magara, D. Miyai, E. Kuroki, H. Nishimura, S. Furudoi, and T. Komori Inhibitory effect of roxithromycin on the local levels of bone-resorbing cytokines in an experimental model of murine osteomyelitis J. Antimicrob. Chemother., August 1, 2002; 50(2): 289 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Vazifeh, H. Abdelghaffar, and M. T. Labro Effect of Telithromycin (HMR 3647) on Polymorphonuclear Neutrophil Killing of Staphylococcus aureus in Comparison with Roxithromycin Antimicrob. Agents Chemother., May 1, 2002; 46(5): 1364 - 1374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Saiman, Y. Chen, P. S. Gabriel, and C. Knirsch Synergistic Activities of Macrolide Antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans Isolated from Patients with Cystic Fibrosis Antimicrob. Agents Chemother., April 1, 2002; 46(4): 1105 - 1107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Parchure, E. G. Zouridakis, and J. C. Kaski Effect of Azithromycin Treatment on Endothelial Function in Patients With Coronary Artery Disease and Evidence of Chlamydia pneumoniae Infection Circulation, March 19, 2002; 105(11): 1298 - 1303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Abdelghaffar, D. Vazifeh, and M. T. Labro Cellular Uptake of Two Fluoroketolides, HMR 3562 and HMR 3787, by Human Polymorphonuclear Neutrophils In Vitro Antimicrob. Agents Chemother., October 1, 2001; 45(10): 2798 - 2806. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. Matsunaga, T. W. Klein, H. Friedman, and Y. Yamamoto Legionella pneumophila Replication in Macrophages Inhibited by Selective Immunomodulatory Effects on Cytokine Formation by Epigallocatechin Gallate, a Major Form of Tea Catechins Infect. Immun., June 1, 2001; 69(6): 3947 - 3953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. Garey, I. Rubinstein, M. H. Gotfried, I. J. Khan, S. Varma, and L. H. Danziger Long-term Clarithromycin Decreases Prednisone Requirements in Elderly Patients With Prednisone-Dependent Asthma Chest, December 1, 2000; 118(6): 1826 - 1827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Lagrou, W. E. Peetermans, M. Jorissen, J. Verhaegen, J. Van Damme, and J. Van Eldere Subinhibitory concentrations of erythromycin reduce pneumococcal adherence to respiratory epithelial cells in vitro J. Antimicrob. Chemother., November 1, 2000; 46(5): 717 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-T. Labro Interference of Antibacterial Agents with Phagocyte Functions: Immunomodulation or ""Immuno-Fairy Tales""? Clin. Microbiol. Rev., October 1, 2000; 13(4): 615 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Noguchi, K. Takada, J. Katayama, A. Emura, and M. Sasatsu Regulation of Transcription of the mph(A) Gene for Macrolide 2'-Phosphotransferase I in Escherichia coli: Characterization of the Regulatory Gene mphR(A) J. Bacteriol., September 15, 2000; 182(18): 5052 - 5058. [Abstract] [Full Text]
|
|
|
|
|
|
C. C. Koch, D. J. Esteban, A. C. Chin, M. E. Olson, R. R. Read, H. Ceri, D. W. Morck, and A. G. Buret Apoptosis, oxidative metabolism and interleukin-8 production in human neutrophils exposed to azithromycin: effects of Streptococcus pneumoniae J. Antimicrob. Chemother., July 1, 2000; 46(1): 19 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Vazifeh, A. Bryskier, and M. T. Labro Effect of Proinflammatory Cytokines on the Interplay between Roxithromycin, HMR 3647, or HMR 3004 and Human Polymorphonuclear Neutrophils Antimicrob. Agents Chemother., March 1, 2000; 44(3): 511 - 521. [Abstract] [Full Text]
|
|
|
|
|
|
J. Sinisalo, K. Mattila, V. Valtonen, O. Anttonen, J. Juvonen, J. Melin, H. Vuorinen-Markkola, M. S. Nieminen, and for the Clarithromycin in Acute Coronary Syndrome Effect of 3 Months of Antimicrobial Treatment With Clarithromycin in Acute Non-Q-Wave Coronary Syndrome Circulation, April 2, 2002; 105(13): 1555 - 1560. [Abstract] [Full Text] [PDF]
|
|